Abstract: Equine influenza viruses (EIV) are a major cause of acute respiratory disease in horses worldwide and occasionally also affect vaccinated animals. Like other influenza A viruses, they undergo antigenic drift, highlighting the importance of both surveillance and virus characterisation in order for vaccine strains to be kept up to date. The aim of the work reported here was to monitor the genetic and antigenic changes occurring in EIV circulating in the UK from 2013 to 2015 and to identify any evidence of vaccine breakdown in the field. Virus isolation, reverse transcription polymerase chain reaction (RT-PCR) and sequencing were performed on EIV-positive nasopharyngeal swab samples submitted to the Diagnostic Laboratory Services at the Animal Health Trust (AHT). Phylogenetic analyses were completed for the haemagglutinin-1 (HA1) and neuraminidase (NA) genes using PhyML and amino acid sequences compared against the current World Organisation for Animal Health (OIE)-recommended Florida clade 2 vaccine strain. Substitutions between the new isolates and the vaccine strain were mapped onto the three-dimensional structure protein structures using PyMol. Antigenic analyses were carried out by haemagglutination inhibition assay using a panel of post-infection ferret antisera. Sixty-nine outbreaks of equine influenza in the UK were reported by the AHT between January 2013 and December 2015. Forty-seven viruses were successfully isolated in eggs from 41 of the outbreaks. Only three cases of vaccine breakdown were identified and in each case the vaccine used contained a virus antigen not currently recommended for equine influenza vaccines. Nucleotide sequencing of the HA and NA genes revealed that all of the viruses belonged to the Florida clade 2 sub-lineage of H3N8 EIV. Phylogenetic and sequence analyses showed that the two sub-populations, previously identified within clade 2, continued to circulate and had accrued further amino acid substitutions. Antigenic characterisation using post-infection ferret antisera in haemagglutination inhibition assays however, failed to detect any marked antigenic differences between the isolates. These findings show that Florida clade 2 EIV continue to circulate in the UK and support the current OIE recommendation to include an example of Florida clade 2 in vaccines.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study focused on examining the evolution and divergence of the H3N8 Equine Influenza Viruses (EIV) in the UK from 2013 to 2015, aiming to identify any changes in these viruses and possible vaccine breakdowns.
Methodology
Virus isolation, reverse transcription polymerase chain reaction (RT-PCR), and sequencing were performed on EIV-positive nasopharyngeal swab samples submitted to the Diagnostic Laboratory Services at the Animal Health Trust (AHT).
Phylogenetic analyses were completed for the haemagglutinin-1 (HA1) and neuraminidase (NA) genes using PhyML, a tool for phylogenetic reconstruction, and amino acid sequences were compared against the current World Organisation for Animal Health (OIE)-recommended Florida clade 2 vaccine strain.
Substitutions between the new isolates and the vaccine strain were observed by mapping onto the three-dimensional structure protein structures using PyMol, a molecular visualization tool. Antigenic analyses were carried out by haemagglutination inhibition assay using a panel of post-infection ferret antisera.
Findings
Between January 2013 and December 2015, 69 outbreaks of equine influenza in the UK were reported by the AHT. From these, 47 viruses were successfully isolated in eggs from 41 of the outbreaks.
There were only three identified cases of vaccine breakdown, and in each case, the vaccine that was used contained a virus antigen not currently recommended for equine influenza vaccines.
The nucleotide sequencing of the HA and NA genes revealed that all of the viruses belonged to the Florida clade 2 sub-lineage of H3N8 EIV.
Phylogenetic and sequence analyses showed that the previously identified two sub-populations of the Florida clade 2 continued to circulate, with additional amino acid substitutions accrued over time.
Interestingly, no significant antigenic differences were observed between the isolates through antigenic characterisation using post-infection ferret antisera in haemagglutination inhibition assays.
Implications
The findings support the current OIE recommendation to include an example of Florida clade 2 in vaccines as it continues to circulate in the UK.
This research enhances the understanding of EIV evolution, highlighting the need for continued monitoring of the virus to ensure the effectiveness of existing vaccines and inform the development of new ones.
Cite This Article
APA
Rash A, Morton R, Woodward A, Maes O, McCauley J, Bryant N, Elton D.
(2017).
Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015.
Pathogens, 6(1), 6.
https://doi.org/10.3390/pathogens6010006
Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK. adam.rash@aht.org.uk.
Morton, Rachel
Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK. Rachel.Morton@aht.org.uk.
Woodward, Alana
Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK. Alana.Woodward@aht.org.uk.
Maes, Olivia
Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK. Olivia.Maes@aht.org.uk.
McCauley, John
Crick Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. John.McCauley@crick.ac.uk.
Bryant, Neil
Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK. Neil.Bryant@aht.org.uk.
Elton, Debra
Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK. Debra.Elton@aht.org.uk.
Grant Funding
Wellcome Trust
FC001030 / Arthritis Research UK
MC_U117512723 / Medical Research Council
Conflict of Interest Statement
The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
References
This article includes 43 references
Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid.. Nature 1988 Jun 2;333(6172):426-31.
Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.. J Virol 2004 Nov;78(22):12665-7.
Halbherr SJ, Ludersdorfer TH, Ricklin M, Locher S, Berger Rentsch M, Summerfield A, Zimmer G. Biological and protective properties of immune sera directed to the influenza virus neuraminidase.. J Virol 2015 Feb;89(3):1550-63.
Lai AC, Chambers TM, Holland RE Jr, Morley PS, Haines DM, Townsend HG, Barrandeguy M. Diverged evolution of recent equine-2 influenza (H3N8) viruses in the Western Hemisphere.. Arch Virol 2001;146(6):1063-74.
Bernardino PN, Mapes SM, Corbin R, Pusterla N. Pyrosequencing as a fast and reliable tool to determine clade affiliation for equine Influenza A virus.. J Vet Diagn Invest 2016 May 1;28(3):323-326.
. The World Organisation for Animal Health (OIE) Expert surveillance panel on equine influenza vaccine composition—Conclusions and recommendations.. Off. Int. Epizoot. Bull. 2016;2:61–63.
. GISAID EpiFlu Database Editorial: Action stations: The time for sitting on flu data is over.. Nature 2006;441:1028.
Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.. Nature 2006 Sep 7;443(7107):45-9.
. The World Organisation for Animal Health (OIE) Expert surveillance panel on equine influenza vaccine composition—Conclusions and recommendations.. Off. Int. Epizoot. Bull. 2010;2:44–45.
Dreyfus C, Ekiert DC, Wilson IA. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin.. J Virol 2013 Jun;87(12):7149-54.
Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0.. Syst Biol 2010 May;59(3):307-21.
Burashev Y, Orynbayev M, Zakarya K, Abduraimov Y, Kassenov M, Strochkov V, Kozhabergenov N, Usserbayev B, Melisbek A, Shirinbekov M, Sypatay N, Sultankulova K. Complete Coding Genome Sequence of an Influenza A/H3N8 Equine Virus Isolated in Kazakhstan in 2007. Microbiol Resour Announc 2022 Oct 20;11(10):e0114721.
Oli AN, Obialor WO, Ifeanyichukwu MO, Odimegwu DC, Okoyeh JN, Emechebe GO, Adejumo SA, Ibeanu GC. Immunoinformatics and Vaccine Development: An Overview. Immunotargets Ther 2020;9:13-30.
Kwaśnik M, Góra IM, Żmudziński JF, Rola J, Polak MP, Rożek W. Genetic Analysis of the M Gene of Equine Influenza Virus Strains Isolated in Poland, in the Context of the Asian-like Group Formation. J Vet Res 2018 Dec;62(4):405-412.
Nemoto M, Yamanaka T, Bannai H, Tsujimura K, Kokado H. Complete Genomic Sequences of H3N8 Equine Influenza Virus Strains Used as Vaccine Strains in Japan. Genome Announc 2018 Mar 22;6(12).
Kökkaya S, Göksu AG, Sözdutmaz İ, Toy MA, Berber E. Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges. Vet Res Commun 2025 Oct 22;49(6):366.
Zhang Y, Guo X, Yu M, Sun L, Qu Y, Guo K, Hu Z, Liu D, Zhang H, Wang X. Equine ANP32 proteins support influenza A virus RNA polymerase activity. Virol Sin 2023 Oct 27;38(6):951-60.
Najarro G, Brackett K, Woosley H, Dorman LC, Turon-Lagot V, Khadka S, Faeldonea C, Moreno OK, Negron AR, Love C, Ward R, Langelier C, McCarthy F, Gonzalez C, Elias JE, Gardner BM, Arias C. BiP/GRP78 is a pro-viral factor for diverse dsDNA viruses that promotes the survival and proliferation of cells upon KSHV infection. PLoS Pathog 2024 Oct;20(10):e1012660.